ArticleThe Journal of experimental medicine2007
IgG1 B cell receptor signaling is inhibited by CD22 and promotes the development of B cells whose survival is less dependent on Ig alpha/beta.
Article in The Journal of experimental medicine, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 82 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
82 citing papers in PubMed, 126 citations in OpenAlex.
- Antibody-mediated diversification of primary and secondary humoral immune responses.The Journal of experimental medicine · 2026Article
- The B-cell Receptor Blueprint in Lymphoma: Mechanisms and Therapeutic Opportunities.Blood cancer discovery · 2026Review
- Cerebral ischaemic stroke results in altered mucosal antibody responses and host-commensal microbiota interactions.Brain, behavior, and immunity · 2026Article
- Article
- Antibody Mediated Diversification of Primary and Secondary Immune Responses.bioRxiv : the preprint server for biology · 2025Article
- IgM and IgG1 B cell receptors differentially affect B cell fates and dictate the pathogenesis of mature B cell lymphomas.Science advances · 2025Article
- B-cell Receptor Silencing Reveals the Origin and Dependencies of High-Grade B-cell Lymphomas with MYC and BCL2 Rearrangements.Blood cancer discovery · 2025Article
- Blocking plasma cell fate enhances antigen-specific presentation by B cells to boost anti-tumor immunity.Nature communications · 2025Article
- EZH2 coordinates memory B-cell programming and recall responses.Journal of immunology (Baltimore, Md. : 1950) · 2025Article
- Regulation of BCR-mediated CaScience immunology · 2024Article
- Natural antibodies are required for clearance of necrotic cells and recovery from acute liver injury.JHEP reports : innovation in hepatology · 2024Article
- The multifaceted roles of B lymphocytes in metabolic dysfunction-associated steatotic liver disease.Frontiers in immunology · 2024Review
- Intestinal B cells license metabolic T-cell activation in NASH microbiota/antigen-independently and contribute to fibrosis by IgA-FcR signalling.Journal of hepatology · 2023Article
- An Optimized Flow Cytometric Method to Demonstrate the Differentiation Stage-Dependent CaInternational journal of molecular sciences · 2023Article
- Role of B Lymphocytes in the Pathogenesis of NAFLD: A 2022 Update.International journal of molecular sciences · 2022Review
- Rhythmicity of intestinal IgA responses confers oscillatory commensal microbiota mutualism.Science immunology · 2022Article
- Cross-reactive, natural IgG recognizing L. major promote parasite internalization by dendritic cells and promote protective immunity.Journal of molecular medicine (Berlin, Germany) · 2022Article
- B Lymphocyte-Deficiency in Mice Causes Vascular Dysfunction by Inducing Neutrophilia.Biomedicines · 2021Article
- Critical requirement for BCR, BAFF, and BAFFR in memory B cell survival.The Journal of experimental medicine · 2021Article
- Functional Role of B Cells in Atherosclerosis.Cells · 2021Review
22 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 6 institutions in 5 countries.
Funding
Abstract
We describe a mouse strain in which B cell development relies either on the expression of membrane-bound immunoglobulin (Ig) gamma1 or mu heavy chains. Progenitor cells expressing gamma1 chains from the beginning generate a peripheral B cell compartment of normal size with all subsets, but a partial block is seen at the pro- to pre-B cell transition. Accordingly, gamma1-driven B cell development is disfavored in competition with developing B cells expressing a wild-type (WT) IgH locus. However, the mutant B cells display a long half-life and accumulate in the mature B cell compartment, and even though partial truncation of the Ig alpha cytoplasmic tail compromises their development, it does not affect their maintenance, as it does in WT cells. IgG1-expressing B cells showed an enhanced Ca(2+) response upon B cell receptor cross-linking, which was not due to a lack of inhibition by CD22. The enhanced Ca(2+) response was also observed in mature B cells that had been switched from IgM to IgG1 expression in vivo. Collectively, these results suggest that the gamma1 chain can exert a unique signaling function that can partially replace that of the Ig alpha/beta heterodimer in B cell maintenance and may contribute to memory B cell physiology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.